Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Ca… Read more
Pulse Biosciences Inc (PLSE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.141x
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has a cash flow conversion efficiency ratio of -0.141x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.04 Million) by net assets ($92.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pulse Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Pulse Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pulse Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulse Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinosun Tech
SHE:300333
|
0.004x |
|
Guangdong Skychem Technology Co. Ltd. A
SHG:688603
|
-0.005x |
|
Universal Stainless & Alloy
NASDAQ:USAP
|
0.047x |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
0.022x |
|
LINK MOB.GRP.HLDG.NK-005
F:L1N
|
N/A |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
N/A |
|
Safari Industries (India) Limited
NSE:SAFARI
|
0.059x |
|
One Liberty Properties Inc
NYSE:OLP
|
0.015x |
Annual Cash Flow Conversion Efficiency for Pulse Biosciences Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $114.86 Million | $-36.34 Million | -0.316x | +57.52% |
| 2023-12-31 | $44.36 Million | $-33.04 Million | -0.745x | -103.56% |
| 2022-12-31 | $-2.25 Million | $-47.01 Million | 20.913x | +1479.73% |
| 2021-12-31 | $35.69 Million | $-54.10 Million | -1.516x | +1.88% |
| 2020-12-31 | $22.89 Million | $-35.37 Million | -1.545x | -38.89% |
| 2019-12-31 | $30.74 Million | $-34.19 Million | -1.112x | -208.73% |
| 2018-12-31 | $66.33 Million | $-23.90 Million | -0.360x | -49.45% |
| 2017-12-31 | $45.99 Million | $-11.09 Million | -0.241x | +24.26% |
| 2016-12-31 | $25.30 Million | $-8.05 Million | -0.318x | -31.12% |
| 2015-12-31 | $13.67 Million | $-3.32 Million | -0.243x | -2153.35% |
| 2014-12-31 | $16.07 Million | $-173.14K | -0.011x | -- |